MapLight Therapeutics

MapLight Therapeutics ROE

The Return on Equity (ROE) of MapLight Therapeutics (MPLT) as of Oct 22, 2026 is -35.16 %. In the previous year, Return on Equity (ROE) was -67.35 % — a change of -47.80% (higher).

ROE

-35.16 %

YoY

-47.80%

Last updated:

In 2025, MapLight Therapeutics's return on equity (ROE) was -35.16 %, a -47.80% increase from the -67.35 % ROE in the previous year.

The MapLight Therapeutics ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2022
-143.82 USD
Jan 1, 2023
-78.15 USD
Jan 1, 2024
-67.35 USD
Jan 1, 2025
-35.16 USD
The MapLight Therapeutics ROE history
YEARROEYoY
-35.16 %-47.80%
-67.35 %-13.83%
-78.15 %-45.66%
-143.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

MapLight Therapeutics Stock analysis

What does MapLight Therapeutics do? MapLight Therapeutics develops novel therapeutics for brain disorders, focusing on central nervous system conditions. Its lead product ML-007C-MA combines an M1/M4 muscarinic agonist with a peripherally acting anticholinergic for schizophrenia and Alzheimer’s disease psychosis treatment. The second product ML-004 targets autism spectrum disorder symptoms as a 5-HT1B/1D agonist. The company advances preclinical programs ML-021 and ML-009, aiming to address unmet medical needs in CNS disorders. MapLight Therapeutics generates revenue through the development and potential commercialization of its product candidates. Investors and pharmaceutical partners fund the company’s clinical and preclinical research. The company’s focus on CNS disorders attracts biopharmaceutical investors seeking innovative treatments for conditions like schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder. Its product pipeline targets patients with debilitating CNS conditions requiring new therapeutic options. The company’s lead candidate ML-007C-MA is designed to activate M1 and M4 muscarinic receptors in the CNS while minimizing peripheral side effects. ML-004 targets social communication deficits and irritability in autism spectrum disorder. Preclinical programs ML-021 and ML-009 represent future potential revenue streams. MapLight’s development stage indicates it is not yet generating sales but is positioned for future commercialization as clinical trials progress. MapLight Therapeutics is one of the most popular companies on Eulerpool.

ROE Details

Decoding MapLight Therapeutics's Return on Equity (ROE)

MapLight Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing MapLight Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

MapLight Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in MapLight Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about MapLight Therapeutics stock

Return on Equity (ROE) of MapLight Therapeutics is -35.16 % in 2025.

Return on Equity (ROE) of MapLight Therapeutics changed from -67.35 % to -35.16 %, representing a -47.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) MapLight Therapeutics since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s MapLight Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — MapLight Therapeutics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — MapLight Therapeutics